Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 2
2019 2
2020 4
2021 2
2022 4
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer.
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F. Kinose Y, et al. Among authors: gitto sb. Res Sq [Preprint]. 2023 Sep 27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1. Res Sq. 2023. PMID: 37841875 Free PMC article. Preprint.
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Pantel AR, Gitto SB, Makvandi M, Kim H, Medvedv S, Weeks JK, Torigian DA, Hsieh CJ, Ferman B, Latif NA, Tanyi JL, Martin LP, Lanzo SM, Liu F, Cao Q, Mills GB, Doot RK, Mankoff DA, Mach RH, Lin LL, Simpkins F. Pantel AR, et al. Among authors: gitto sb. Clin Cancer Res. 2023 Apr 14;29(8):1515-1527. doi: 10.1158/1078-0432.CCR-22-1602. Clin Cancer Res. 2023. PMID: 36441795
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma.
Makvandi M, Samanta M, Martorano P, Lee H, Gitto SB, Patel K, Groff D, Pogoriler J, Martinez D, Riad A, Dabagian H, Zaleski M, Taghvaee T, Xu K, Lee JY, Hou C, Farrel A, Batra V, Carlin SD, Powell DJ Jr, Mach RH, Pryma DA, Maris JM. Makvandi M, et al. Among authors: gitto sb. Commun Biol. 2022 Nov 17;5(1):1260. doi: 10.1038/s42003-022-04209-8. Commun Biol. 2022. PMID: 36396952 Free PMC article.
Adoptive T cell therapy for ovarian cancer.
Gitto SB, Ihewulezi CJN, Powell DJ Jr. Gitto SB, et al. Gynecol Oncol. 2024 Apr 10;186:77-84. doi: 10.1016/j.ygyno.2024.04.001. Online ahead of print. Gynecol Oncol. 2024. PMID: 38603955 Review.
PD-L1 blockade enhances anti-tumor efficacy of NK cells.
Oyer JL, Gitto SB, Altomare DA, Copik AJ. Oyer JL, et al. Among authors: gitto sb. Oncoimmunology. 2018 Aug 27;7(11):e1509819. doi: 10.1080/2162402X.2018.1509819. eCollection 2018. Oncoimmunology. 2018. PMID: 30377572 Free PMC article.
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Tubridy EA, Eiva MA, Liu F, Omran DK, Gysler S, Brown EG, Roy AG, Zeng Y, Oh J, Cao Q, Gitto SB, Powell DJ Jr. Tubridy EA, et al. Among authors: gitto sb. Gynecol Oncol. 2024 Jan 29;184:74-82. doi: 10.1016/j.ygyno.2024.01.029. Online ahead of print. Gynecol Oncol. 2024. PMID: 38290413
20 results